LEXINGTON, Mass., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the election of Ms.

LEXINGTON, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, announced the initiation of the

160 patient balstilimab (PD-1) monotherapy trial achieves response rates of 14% in all treated patients and 19% in PD-L1 positive patients 155 patient balstilimab (PD-1) + zalifrelimab (CTLA-4) combination trial achieves response rates of 22% in all patients and 27% in PD-L1 positive patients

LEXINGTON, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr.

LEXINGTON, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr.

LEXINGTON, Mass. , Aug. 31, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the election of Mr.

Data from two Phase 2 trials of balstilimab +/- zalifrelimab in patients with refractory cervical cancer were accepted as part of a late-breaking abstract and will be presented as an oral presentation on September 18, 2020 at ESMO LEXINGTON, Mass. , Aug. 26, 2020 /PRNewswire/ -- Agenus Inc.

- Dr. Chuck Drake & Dr. Bree Wilky to discuss AGEN1181 & zalifrelimab - new responses - AGEN2373 achieves durable SDs in early Ph1; balstilimab combos to start - Zalifrelimab achieves responses in PD-1 failures (1CR, 3PRs); Ph2 expansion underway - Next-gen CTLA-4, PD-1 & iNKT activating therapy

LEXINGTON, Mass., Aug. 4, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, announced today that Dr.

Video Meeting on Thursday August 6, 2020 from 8:30 - 10:30 am LEXINGTON, Mass., July 29, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to